All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors for whom no further effective standard treatment is available.
Diffuse Large B-cell Lymphoma
Oct 03, 2016
Jan 25, 2021
18 Years and older (Adult, Older Adult)
Eastern Cooperative Oncology Group (ECOG): 0 to 2
Relapsed or refractory diffuse large B cell lymphoma with measurable disease as determined by Non-Hodgkin's Lymphoma Cheson response criteria (2014)
Advanced or recurrent/metastatic solid tumor, including nasopharyngeal carcinoma, castration-resistant prostate cancer, gastric cancer, ovarian clear cell carcinoma and sarcoma, with measurable disease as determined by RECIST 1.1.
Other malignant diseases than the ones being treated in this study
Severe and/or uncontrolled medical conditions that in the investigator's opinion could affect the safety of individual or impair the assessment of study result.
B-cell lymphoma patients who have received prior allogeneic stem cell transplant
Patient have received anti-cancer therapies within defined time frames prior to the first dose of study treatment
Symptomatic central nervous system (CNS) involvement which are neurologically unstable or requiring increasing doses of steroids to control.
Patient having out of range laboratory values defined as:
1) Insufficient bone marrow function at screening:
Platelets ≤ 50,000/mm3
Hemoglobin (Hgb) ≤ 80 g/L
Absolute neutrophil count (ANC) ≤ 1000/mm3 2) Insufficient hepatic and renal function at screening:
ALP, ALT, and AST > 3 x ULN (>5 x ULN if subject has liver metastases)
Total bilirubin >1.5 x ULN
Serum creatinine > 1.5 x ULN and/or creatinine clearance ≤ 50 mL/min
University of California San Francisco
San Francisco, 94115
UCLA Santa Monica Hematology / Oncology
Santa Monica, 90404
University of Texas MD Anderson Cancer Center Dept of Onc